Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab

Osteoporosis International

Volumn 25, Issue 1, 2014, Pages 393-395

  Neuprez, A ^a,b   Coste, S ^c   Rompen, E ^b   Crielaard, J M ^b   Reginster, J Y ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Gynecology Department   (Belgium)

Author keywords

Denosumab; Jaw; Osteonecrosis; Osteoporosis

Indexed keywords

CALCIUM; DENOSUMAB; PARATHYROID HORMONE[1-34]; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; CASE REPORT; CLINICAL EXAMINATION; HUMAN; IDIOPATHIC OSTEOPOROSIS; JAW OSTEONECROSIS; MIDDLE AGED; PHYSICIAN; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RIB FRACTURE; TOOTH EXTRACTION; VERTEBRA MALFORMATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; HUMANS; MALE; MANDIBULAR DISEASES; MIDDLE AGED; OSTEONECROSIS; OSTEOPOROSIS; RANK LIGAND; TOMOGRAPHY, X-RAY COMPUTED; TOOTH EXTRACTION;

EID: 84891851925     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2437-z     Document Type: Article

References (19)

1. Kaufman JM, Reginster JY, Boonen S, Brandi ML, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA, McCloskey E, Mitlak B, Orwoll E, Ringe JD, Weryha G, Rizzoli R (2013) Treatment of osteoporosis in men. Bone 53:134-144
2. Kaufman JM, Goemaere S (2008) Osteoporosis in men. Best Pract Res Clin Endocrinol Metab 22:787-812
3. Rizzoli R, Boonen S, Brandi ML, Bruyère O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryha G, Reginster JY (2013) Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 29:305-313
4. Cavalier E, Delanaye P, Moranne O (2013) Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kindey Dis 61:847-848
5. Johansson H, Kanis JA, McCloskey EV, Oden A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyère O, Reginster JY (2011) A FRAX model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453-461
6. Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A, Bruyère O, Hiligsmann M, Devogelaer JP, Kaufman JM, Reginster JY (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liège 64:612-619
7. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066 (Pubitemid 41110556)
8. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23-57
9. Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161-3169
10. Parthan A, Kruse MM, Agodoa I, Tao CY, Silverman SL, Orwoll E (2013) Is denosumab cost-effective compared to oral bisphosphonates for the treatment of male osteoporosis (mop) in Sweden? Value Health 16:A223
11. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841-847
12. Ruggiera SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534 (Pubitemid 38542516)
13. Subramanian G, Cohen HV, Quek SY (2011) A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:744-753
14. Aghaloo TL, Felsenfeld AL, Tetradis S (2010) Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 68:959-963
15. Raylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48:221-223
16. Diz P, Lopez-Cedrun JL, Arenaz J, Scully C (2012) Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc 143:981-984
17. Pichardo SE, Kuypers SC, Van Merkesteyn JP (2013) Denosumab osteonecrosis of the mandible: a new entity? A case report. J Craniomaxillofac Surg 41:e65-e69
18. Qi WX, Tang LN, He AN, Yao Y (2013) Shen Z Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol (in press)
19. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellström D, Radominski SC, Reginster JY, Resch H, Roman Ivorra JA, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694-701